Union Commerce and Industry Minister Piyush Goyal on Thursday underlined the government’s continued focus on empowering India’s farming community, citing multiple initiatives aimed at ensuring agricultural sustainability, better incomes, and global competitiveness.
Speaking at the 16th Agriculture Leadership Conclave in New Delhi, Goyal said over 25 crore Soil Health Cards have been distributed to farmers across the country, promoting balanced fertiliser use and improved productivity. The Kisan Credit Card scheme, he added, has enhanced access to institutional credit for millions of farmers.
Reiterating the Centre’s commitment to farmers, the minister said agriculture has remained central to the government’s development agenda under Prime Minister Narendra Modi. Direct income support under the PM-KISAN Samman Nidhi scheme, he noted, has benefited a large number of rural families.
To strengthen agri-marketing, Goyal said 1,400 mandis have been integrated with the e-NAM platform, offering farmers real-time price information and wider market access.
Goyal also highlighted efforts to keep fertilisers affordable, pointing to the continuation of subsidies and uninterrupted supply during the COVID-19 pandemic. Lauding farmers for maintaining stable agri-exports despite global headwinds, he said exports from agriculture, animal husbandry, and fisheries stood at ₹4 lakh crore in 2023–24.
Basmati rice, spices, fresh produce, fisheries, and poultry continued to drive agri-export growth, supported by trade deals with Australia, the UAE, EFTA countries, and the UK, he added.
Looking ahead, Goyal identified key growth areas including seed production, organic farming, and drip irrigation. He said digital technologies like AI, geospatial mapping, and weather forecasting tools are being integrated to modernise agriculture and empower Farmer Producer Organisations (FPOs).
The minister also stressed the need for value addition through food processing, branding, and improved packaging. He said the government is focusing on warehousing and storage infrastructure with dedicated funds for agriculture, fisheries, and animal husbandry.
“Under the vision of Viksit Bharat, agriculture will remain a core pillar of India’s growth story,” he stressed.
Union Commerce and Industry Minister Piyush Goyal on Thursday underlined the government’s continued focus on empowering India’s farming community, citing multiple initiatives aimed at ensuring agricultural sustainability, better incomes, and global competitiveness.
Speaking at the 16th Agriculture Leadership Conclave in New Delhi, Goyal said over 25 crore Soil Health Cards have been distributed to farmers across the country, promoting balanced fertiliser use and improved productivity. The Kisan Credit Card scheme, he added, has enhanced access to institutional credit for millions of farmers.
Reiterating the Centre’s commitment to farmers, the minister said agriculture has remained central to the government’s development agenda under Prime Minister Narendra Modi. Direct income support under the PM-KISAN Samman Nidhi scheme, he noted, has benefited a large number of rural families.
To strengthen agri-marketing, Goyal said 1,400 mandis have been integrated with the e-NAM platform, offering farmers real-time price information and wider market access.
Goyal also highlighted efforts to keep fertilisers affordable, pointing to the continuation of subsidies and uninterrupted supply during the COVID-19 pandemic. Lauding farmers for maintaining stable agri-exports despite global headwinds, he said exports from agriculture, animal husbandry, and fisheries stood at ₹4 lakh crore in 2023–24.
Basmati rice, spices, fresh produce, fisheries, and poultry continued to drive agri-export growth, supported by trade deals with Australia, the UAE, EFTA countries, and the UK, he added.
Looking ahead, Goyal identified key growth areas including seed production, organic farming, and drip irrigation. He said digital technologies like AI, geospatial mapping, and weather forecasting tools are being integrated to modernise agriculture and empower Farmer Producer Organisations (FPOs).
The minister also stressed the need for value addition through food processing, branding, and improved packaging. He said the government is focusing on warehousing and storage infrastructure with dedicated funds for agriculture, fisheries, and animal husbandry.
“Under the vision of Viksit Bharat, agriculture will remain a core pillar of India’s growth story,” he stressed.
Source: US Department of Health and Human Services – 3
This recall involves updating instructions for using devices and does not involve removing them from where they are used or sold. The FDA has identified this recall as the most serious type. This device may cause serious injury or death if you continue to use it without following the updated instructions. Affected Product Product Names:
Ballard Closed Suction System for Neonates/Pediatrics, 8 F, Y-Adapter Ballard Closed Suction System for Neonates/Pediatrics, 10 F, Elbow Ballard Closed Suction System for Neonates/Pediatrics, 8 F, Elbow Ballard Closed Suction System for Adults, 14 F, T-Piece Ballard Closed Suction System for Adults, 14 F, DSE Ballard Turbo-Cleaning Closed Suction System for Adults, 14 F, DSE, MDI Ballard Turbo-Cleaning Closed Suction System for Adults, 14 F, DSE
Full List of Affected Devices:
Product Description REF Number Lot Number UDI Information
Ballard Closed Suction System for Neonates/Pediatrics, 8 F, Y-Adapter (Each) 198 1561168 00609038938264
Ballard Closed Suction System for Neonates/Pediatrics, 8 F, Y-Adapter (DSP) 198 1561168 10609038938261
Ballard Closed Suction System for Neonates/Pediatrics, 8 F, Y-Adapter (Case) 198 1561168 20609038938268
Ballard Closed Suction System for Neonates/Pediatrics, 10 F, Elbow 210 1561165 00609038938349
Ballard Closed Suction System for Neonates/Pediatrics, 8 F, Elbow 20083 15552151555217 00609038938311
Ballard Closed Suction System for Adults, 14 F, T-Piece 220135 15554531564227 00609038944920
Ballard Closed Suction System for Adults, 14 F, DSE 2210-5 1555424 00609038983103
Ballard Turbo-Cleaning Closed Suction System for Adults, 14 F, DSE, MDI 2271418-5 1555430 00609038982632
Ballard Turbo-Cleaning Closed Suction System for Adults, 14 F, DSE 227-5 1555468 00609038989655
What to Do Do not use the identified affected products listed in the table above. On March 19, 2025, Avanos Medical, Inc. sent all affected customers an Urgent Medical Device Recall Notice recommending the following actions:
Check your inventory for the affected products listed above. Stop using any affected products immediately and set them aside in a secure location (quarantine them). Fill out and email the attached Response Form to productquality@myairlife.com as soon as possible. This helps document what you have and confirms you received this notice. If you shared this product with others, please let those customers know about the recall. You can include a copy of this letter when notifying them. Return or confirm destruction of the affected products. Once you do, AirLife will send you replacements. For urgent needs, call AirLife at 1-800-433-2797. Inform all staff in your organization who need to know about this recall.
Reason for Early Alert Avanos Medical, Inc. is recalling Ballard Closed Suction Systems due to a failure in the sterilization process. Use of the affected product may cause serious adverse health consequences, including infection, airway injury, prolonged inflammation, sepsis, or death. To date, Avanos Medical, Inc. has not reported any serious injuries or deaths associated with this issue. Device Use Ballard Closed Suction Systems are used to remove secretions from the airway in patients receiving mechanical ventilation, minimizing the risks associated with disconnecting the ventilator circuit. Contact Information Customers in the U.S. with questions about this recall should contact Avanos Medical, Inc. at 1-800-433-2797. Additional FDA Resources (listed in order of most to least recent):
Unique Device Identifier (UDI) The unique device identifier (UDI) helps identify individual medical devices sold in the United States from distribution to use. The UDI allows for more accurate reporting, reviewing, and analyzing of adverse event reports so that devices can be identified more quickly, and as a result, problems potentially resolved more quickly.
How do I report a problem? Health care professionals and consumers may report adverse reactions or quality problems they experienced using these devices to MedWatch: The FDA Safety Information and Adverse Event Reporting Program.
Question for written answer E-002696/2025 to the Commission Rule 144 Anja Hazekamp (The Left)
Amid ongoing safety concerns, glyphosate remains the most widely used pesticide in the EU. In 2015, the International Agency for Research on Cancer found glyphosate to be carcinogenic to animals and probably to humans[1]. A Parliament appeal to ban glyphosate was ignored[2].
The Commission has stated ‘if evidence emerges that indicates that the approval criteria are no longer fulfilled, a review of the approval at EU level may be initiated at any time and the Commission will take action immediately to amend or withdraw the approval if this is scientifically warranted’[3].
Now, a new Environmental Health study confirms that glyphosate has probable carcinogenic effects after long-term exposure to ‘safe’ doses[4].
Considering these findings:
1.Does the Commission maintain its claim that using glyphosate until 2033 is safe, and if so, how is this assessment justified?
2.What steps will it take in response to the study, for example, is it willing to immediately trigger a review of the approval, as provided for in Article 21 of Regulation (EC) No 1107/2009, as the study suggests glyphosate meets the cut-off criteria, and to prepare an immediate withdrawal of the approval?
3.Why does the Commission prioritise uncritical, industry-financed studies over impartial research?
Source: Hong Kong Government special administrative region – 4
The Secretary for Health, Professor Lo Chung-mau, will depart for Nanjing tomorrow (July 11) to meet with health officials of Jiangsu Province and introduce them to the latest developments of various healthcare policies in Hong Kong as well as attend the 13th Nanjing Academic Symposium on Hepatobiliary Surgery and Liver Transplantation, with a view to deepening exchanges and collaboration on healthcare-related areas with the Mainland.
During his visit to Nanjing, Professor Lo will also visit local pharmaceutical companies and hospitals to introduce the latest progress in enhancing Hong Kong’s drug approval mechanism and registration regime, and share the city’s experiences in strengthening hospital management and services respectively.
Accompanying Professor Lo on the visit are the Assistant Director of Health (Drug), Mr Frank Chan; the Director (Quality and Safety) of the Hospital Authority (HA), Dr Michael Wong; and the Cluster Chief Executive of Hong Kong West Cluster of the HA, Dr Theresa Li.
Professor Lo will return to Hong Kong in the afternoon on July 12. During his absence, the Under Secretary for Health, Dr Libby Lee, will be the Acting Secretary for Health.
Nzimande places science and innovation at core of long-term sustainability
The Minister of Science, Technology, and Innovation, Professor Blade Nzimande, says South Africa must prioritise science, technology and innovation (STI) to achieve long-term sustainability.
“We deliver this Budget Vote against the background of a complex set of national and global challenges, some of which include economic stagnation, rising social inequality, a breakdown of social cohesion, the negative impact of climate change, technological disruption and new tensions arising from changes in the international economic and political system,” said the Minister while tabling the department’s Budget Vote on Wednesday in Parliament.
He committed to taking STI to the villages, townships, and all the corners of South Africa.
“We hold the view that our country must place science, technology, and innovation at the centre of government, education, industry, and society if we are to secure our sovereignty and future sustainability.”
Nzimande highlighted his department’s dedication to speeding up the transformation and growth of human resources and the research workforce in STI.
The Minister stated that this commitment includes advancing the Presidential PhD Programme, which was launched in 2023.
“We will scale up the implementation of the Innovation Fund programme. During this financial year, our target is to support between 10 and 15 venture capital funds through strategic partnerships with, among others, our entity, the Technology Innovation Agency (TIA).”
He stressed that the development of critical scientific skills remains central to the department’s mandate.
According to the department, 288 Research Chairs to 22 universities and national research facilities in various research disciplines have been awarded.
“I am, however, deeply concerned that black researchers and historically disadvantaged institutions (HDIs) have not benefited from this initiative in the manner that we had anticipated,” the Minister said.
To tackle this issue, his department is collaborating with the National Research Foundation (NRF) to establish Research Chairs aimed at addressing these and other deficits in transformation.
“Further to this, our National System of Innovation (NSI) is still characterised by several other transformation deficits, including the low participation of women at the highest levels.”
The department is also strengthening the coordination and direction of the NSI through the Inter-Ministerial Committee on STI, Presidential Plenary for STI, and policy coordination instruments.
In March this year, South Africa hosted its first NSI Transformation Summit.
The Minister announced that under the leadership of the department’s Director-General, the resolutions of this summit are being incorporated into their strategic plan.
In addition, he has vowed continued support for Palestinian institutions and researchers, adding that this project is making steady progress.
As part of South Africa’s G20 Presidency, the department is committed to advancing STI priorities for both the nation and the African continent.
The department is also working tirelessly to increase the Gross Expenditure on Research and Development to 1.5%.
This includes establishing a strategic agreement among organised business, government, and labour to determine future funding.
In addition, the department is focused on maintaining and upgrading crucial science infrastructure and projects, including the Square Kilometre Array (SKA), Nuclear Medicine Research Infrastructure (NuMeRi), and the development of reliable pandemic preparedness capacity.
Another priority is to build strategic innovation partnerships, which involves aligning the key focus areas of the STI Decadal Plan with the relevant line function departments and mobilising additional funding and resources. He said significant programmes in areas such as artificial intelligence, energy security, space exploration, vaccine manufacturing, and indigenous knowledge systems (IKS) will be scaled up.
Nzimande stressed that efforts are underway to raise public awareness about the important contributions of the NSI to human development, supported by a vigorous public engagement and communication campaign. – SAnews.gov.za
National Treasury has allocated R753 million to the Department of Health — under Section 16 of the Public Finance Management Act (PFMA) — to help bridge the shortfall caused by the United States’ decision to cut HIV and tuberculosis (TB) grants.
Health Minister Dr Aaron Motsoaledi made the announcement on Wednesday during the Budget Vote presentation in Parliament.
According to the Minister, R590 million of the total of R753 million will be allocated for service delivery in the provinces, distributed through the comprehensive HIV/Aids component of the District Health Programme Grant.
In addition, R32.1 million will be given to the National Department of Health to support the Central Chronic Medicine Dispensing and Distribution (CCMDD) Programme, as well as pharmaceutical supply chain management.
Furthermore, R132 million will be transferred to the South African Medical Research Council (SAMRC) to enhance health research across the country.
“This is how it is going to work: the Bill and Melinda Gates Foundation and the Wellcome Trust have pledged R100 million each.
“They put a condition that each R100 million they contribute be matched by R200 million from our own Treasury, and that money be given to researchers. Treasury duly agreed.”
This means South Africa will receive a total of R600 million allocated to researchers, even though the President’s Emergency Plan for AIDS Relief (PEPFAR) has withdrawn support.
The United States government’s withdrawal of funding to key health initiatives, including PEPFAR, which was established by former President George W Bush in 2003, led to a loss of R7.9 billion spent on HIV/Aids programmes annually.
“Hence, the Bill and Melinda Gates Foundation and the Wellcome Trust will together immediately release R200 million. On the other hand, the matching R400 million by Treasury will be released over three years, hence the first tranche of R132 million I have mentioned.“
According to the Minister, these funds are meant to address the most urgent needs, with the possibility of additional allocations being considered later.
This week, he stated that the South African Medical Research Council , along with researchers from various institutions and universities, are discussing how they will distribute funds, which will be transferred to the SAMRC.
“We are determined more than ever before to end the scourge of HIV/Aids as a public health threat. Today is a historic day in this regard. As I am speaking to you now, the Global Fund in Geneva is announcing… that it has signed an access agreement with Gilead Sciences to procure lenacapavir,” the Minister said.
The Minister has referred to lenacapavir, a long-acting injection for HIV prevention, as one of the most significant advancements in HIV prevention in decades.
This is the first long-acting injectable treatment for pre-exposure prophylaxis (PrEP), administered twice a year.
According to the Minister, lenacapavir significantly expands the options available for HIV prevention, offering the most choices ever.
“For South Africa, we regard this as a game changer in our fight against HIV/Aids.
“As such, as South Africa, we have agreed to be one of the first countries in the starting blocks for lenacapavir.”
According to the Minister, the first shipment is expected to arrive in at least one African country by the end of 2025.
“We intend to be such a country, and we have already started putting the plan together. We plan to offer lenacapavir to young women and everyone at risk to stay HIV-free.
“We all know that for far too long, women and girls in our country have carried the greatest burden of this epidemic.” – SAnews.gov.za
The Director is appointed under section 76 of the Act.
About the review
The purpose of the review is to enable the Director to decide whether changes are required to improve ORS C11 2020. The review will consider information on the operation, technical accuracy and clarity of the code of practice.
Call for public submissions
Before reviewing the code of practice, the Director invites public submissions on the review question: ‘Are changes required to improve the Code of Practice for Unsealed Radioactive Material: ORS C11 2020’?
To make a submission, please email ors.codes@health.govt.nz by 5pm, Tuesday 22 July 2025. It will be helpful if you use the subject line: Submission on the review of ORS C11 2020.
About ORS C11 2020
ORS C11 2020 was issued under section 86 of the Act. The purpose of the code of practice is to specify the technical requirements that a person who deals with a radiation source that is subject to the scope of the code of practice must comply with in order to comply with the fundamental requirements of the Act (see sections 9-12 of the Act). The code of practice was also issued to be appropriate to the level of risk posed by the radiation sources and their use.
If the review indicates that changes are required to improve ORS C11 2020, a further public consultation on the proposed changes will be conducted. Information on the review’s findings will be published on this webpage following the completion of the review and this information will indicate the ‘next steps’.
The Director is appointed under section 76 of the Act.
About the review
The purpose of the review is to enable the Director to decide whether changes are required to improve ORS C10 2020. The review will consider information on the operation, technical accuracy and clarity of the code of practice.
Call for public submissions
Before reviewing the code of practice, the Director invites public submissions on the review question: ‘Are changes required to improve the Code of Practice for Irradiating Apparatus: ORS C10 2020’?
To make a submission, please email ors.codes@health.govt.nz by 5pm, Friday 18 July 2025. It will be helpful if you use the subject line: Submission on the review of ORS C10 2020.
About ORS C10 2020
ORS C10 2020 was issued under section 86 of the Act. The purpose of the code of practice is to specify the technical requirements that a person who deals with a radiation source that is subject to the scope of the code of practice must comply with in order to comply with the fundamental requirements of the Act (see sections 9-12 of the Act). The code of practice was also issued to be appropriate to the level of risk posed by the radiation sources and their use.
If the review indicates that changes are required to improve ORS C10 2020, a further public consultation on the proposed changes will be conducted. Information on the review’s findings will be published on this webpage following the completion of the review and this information will indicate the ‘next steps’.
Under section 53 of the Residential Care and Disability Support Services Act 2018, the Director-General of Health has determined the maximum contribution that applies in each region for long-term aged residential care.
The maximum contribution is the maximum weekly amount (inclusive of GST) that a resident assessed as requiring long-term residential care (through a needs assessment and service coordination agency) is required to pay for contracted care services provided to them in the region in which their rest home or continuing care hospital is located.
The maximum contribution is the same for all residents regardless of the type of contracted care services they receive. It is equivalent to the rest home contract price applying to residential care facilities in each region.
The maximum contribution set by this notice applies from 1 July 2025 and replaces the previous maximum contribution notice published in the New Zealand Gazette, 1 September 2024, Notice No. 2024-go4265.
Description of Regions
The appendix of this notice sets out the maximum contribution rates. The appendix contains two parts:
Part 1, which sets out the rates that apply within Territorial Local Authority (TLA) boundaries; and
Part 2, which sets out the rates that apply within specific Statistical Areas, which are smaller subregions within the TLA boundaries specified in Part 1.
The rate specified for the relevant region in Part 1 applies unless the facility is in a statistical area region set out in Part 2, in which case the rate specified in Part 2 applies. This reflects that a higher maximum contribution rate applies in the isolated rural localities represented by the Statistical Area Regions in Part 2 of the Table.
Statistics New Zealand has a geographic boundary viewer that displays the TLA areas and statistical areas in the appendix on a map of New Zealand. See here for more information: Geographic Boundary Viewer.
Health New Zealand will notify residences of the maximum contribution rate that applies to their facility. The facility will inform residents.
Needs Assessment and Service Coordination (NASC) Agencies, Specialised Processing Services, the Ministry of Social Development and residential care providers will also be able to advise the maximum contribution rate for a facility.
The Director is appointed under section 76 of the Act.
About the review
The purpose of the review is to enable the Director to decide whether changes are required to improve ORS C12 2020. The review will consider information on the operation, technical accuracy and clarity of the code of practice.
Call for public submissions
Before reviewing the code of practice, the Director invites public submissions on the review question: ‘Are changes required to improve the Code of Practice for Sealed Radioactive Material: ORS C12 2020’?
To make a submission, please email ors.codes@health.govt.nz by 5pm, Friday 25 July 2025. It will be helpful if you use the subject line: Submission on the review of ORS C12 2020.
About ORS C12 2020
ORS C12 2020 was issued under section 86 of the Act. The purpose of the code of practice is to specify the technical requirements that a person who deals with a radiation source that is subject to the scope of the code of practice must comply with in order to comply with the fundamental requirements of the Act (see sections 9-12 of the Act). The code of practice was also issued to be appropriate to the level of risk posed by the radiation sources and their use.
If the review indicates that changes are required to improve ORS C12 2020, a further public consultation on the proposed changes will be conducted. Information on the review’s findings will be published on this webpage following the completion of the review and this information will indicate the ‘next steps’.
This report shows information on funding to Māori health providers by the Ministry of Health, Health New Zealand, and the disestablished Māori Health Authority for the period 2019/20 to 2023/24. This report follows on from our reports in 2017 and every year from 2021, on the same topic. These reports are part of our monitoring of Whakamaua: Māori Health Action Plan 2020-2053 and the proposed Māori Health Strategy.
Highlights include:
funding to Māori health providers increased from $529.8 million in 2019/20 to $999.8 million in 2023/24, an increase of $469.9 million or 88.7% (see Table 3)
although funding to Māori health providers is increasing, it remains a small but increasing part of Vote Health. It has increased from 3.0% in 2019/20 to 4.4% in 2023/24.
This report differs from previous reports as it now includes data broken down by major service groups. This enables us to see in which areas funding has increased. The top five of 33 major service groups are reported on. These five groups accounted for 81.7% of total funding to Māori health providers in 2023/24.
The top five major service groups reported on are: mental health, Hauora Māori, Primary Health Organisations (PHOs), Public health, and Other community services.
Source: United Kingdom – Executive Government & Departments
News story
Survey reveals high parental confidence in children’s vaccines
UKHSA data shows 85% of parents are confident childhood vaccines are safe, effective and trustworthy.
New data published today by the UK Health Security Agency (UKHSA) shows continued high levels of confidence in the UK’s childhood vaccination programme.
The Childhood vaccines: parental attitudes survey 2025, which tracks parental attitudes towards childhood immunisations across the UK found that most parents believe that childhood vaccines are safe (85% up from 84% in 2023) that they trust them (84% up from 82% in 2024) and they work (87% compared to 89% in 2024).
Parents had a strong awareness of the risks posed by vaccine-preventable diseases, with over 90% (compared to 86% last year) agreeing that pneumonia, meningitis, hepatitis, polio and septicaemia were serious.
The survey also captured parental attitudes towards newer additions to the vaccination schedule. An important new pregnancy vaccine was introduced in September 2025 to help protect babies against Respiratory Syncytial Virus (RSV) and 85% of parents of babies and younger children also rated RSV infection as serious.
Healthcare professionals, in particular GPs, health visitors and nurses, continue to be the most trusted source of vaccine information. 76% of parents had seen or heard information about children’s vaccines in the past year, predominantly from trusted sources including healthcare professionals and official NHS websites. Only 7% ranked the internet and 3% social media in their top three most trusted sources.
Most parents (79%) had already decided that their baby would have all the vaccines offered before they spoke to a health professional. However, following a discussion with a health professional more than half of these parents (53%) said they felt even more confident about their decision, and of those who had decided not to vaccinate 15% changed their mind in favour of vaccination. This is positive news, given the declines in uptake over recent years, and highlights the vital role that knowledgeable health care professionals can play in reversing that decline.
Most parents (80%) reported that they had not seen or heard any concerning information about childhood vaccines, with 12% reporting mixed information and just 3% reporting hearing or seeing information that undermines vaccines. 86% of all parents felt they had received enough information to make an informed decision about vaccines offered to their children.
Dr Julie Yates, UK Health Security Agency’s Deputy Director for Immunisation Programmes:
The findings from our latest survey are encouraging and show that most parents across the UK continue to trust the NHS childhood vaccination programme and understand its importance in protecting our children. It’s particularly reassuring that parents identify healthcare professionals and NHS resources as their most trusted sources of vaccine information. Having questions about vaccines is a normal part of the parental journey. Our survey highlights the crucial role that healthcare professionals play in providing parents with accurate information about vaccines and the serious diseases they protect against, and in building confidence in these programmes. We urge parents with any concerns to speak with a trusted NHS professional such as their GP, Health Visitor, Midwife or Practice Nurse.
However, childhood vaccination rates are still not where we want them to be, and we cannot be complacent. We know that many parents and carers have busy lifestyles, and that finding time to ensure your child attends their appointment can be a challenge. That is why we are working with the NHS and partners to improve access to childhood vaccination services. Getting our rates up to the 95% WHO target required to eliminate these diseases will take sustained effort and a long-term commitment across the public health system, and we are working together and with families and communities to do this.
Dr Amanda Doyle, National Director for Primary Care and Community Services at NHS England, said:
Today’s findings reflect the essential work being done by GPs, health visitors and nurses to reliably inform parents about childhood vaccinations, with more than half of parents saying they felt more confident in getting their children vaccinated after speaking to a healthcare professional, with vaccination one of the best ways to boost public health and prevent illnesses.
Our childhood immunisation programmes are available for free on the NHS as we want to make sure as many children as possible are protected against becoming seriously unwell, and NHS England continues to work closely with vaccination teams, schools and GP services to make it as easy as possible for young people to get their jabs.
Our 10 Year Health Plan aims to build an NHS fit for the future which includes improving access to vaccinations to help put people in control of their own health and I would encourage all parents to act on invites or check vaccination records if they think they may have missed their child’s vaccination.
Source: United Kingdom – Executive Government & Departments
Press release
Toxic lead ammunition banned to protect Britain’s countryside
New ban on use of lead in ammunition to protect iconic wildlife and clean up the nation’s waterways
Red kite perched in a tree
Red kites and white-tailed eagles will receive greater protection thanks to new restrictions on the use of lead in ammunition, Environment Minister Emma Hardy announced today (Thursday 10 July 2025).
To protect iconic British wildlife and clean up the nation’s waterways, new measures will ban shot containing more than 1% lead and bullets with a lead content of more than 3%. Beyond limited exemptions, these types of ammunition will no longer be sold to the public.
The ban will prevent the release of an estimated 7,000 tonnes of the toxic metal into fields, forests and wetlands each year. Up to 100,000 wildfowl, including ducks, swans and waders, die from lead poisoning annually, with birds often confusing the scattered shot for grit and consuming it.
Evidence from the Health and Safety Executive shows lead poses a risk to at least 1 million birds over the coming decades if usage continues at its current rate, while around 40,000 birds of prey such as red kites and white-tailed eagles are at risk from ingesting lead through carrion.
Introducing restrictions will also stop lead from contaminating soil and leaching into rivers when guns are discharged and spread the harmful metal, ensuring ecosystems thrive for both wildlife and people alike.
Environment Minister Emma Hardy said:
Britain is a proud nation of nature lovers, but our rivers are heavily polluted, and majestic birds are declining at an alarming rate.
This new ban on lead in ammunition for most uses will help reverse this – rejuvenating pride in our countryside by protecting precious birdlife and cleaning up rivers.
Non-lead alternatives are readily available, and we’ll continue to work closely with the shooting sector throughout this transition.
Following extensive public engagement, a three-year transition period will support the shooting and hunting sectors to shift to more environmentally friendly alternatives. There will also be a two-year period for outdoor shooting ranges where lead is used to implement measures that prevent pollution from entering the environment.
Alternatives to lead shot have become more efficient and widely available in recent years, with steel and tungsten-based shot being two popular options. The government will continue to engage with the shooting industry to support the transition to alternative ammunition types.
In December 2024, the Health and Safety Executive published their Final Opinion proposing restrictions on the supply and outdoor uses of lead in ammunition – and the government has now taken action to reduce toxic substances from entering the environment.
As part of the restrictions, there will be exemptions in place for the military, police, elite athletes, outdoor target shooting ranges with risk management measures in place, museum collections and other minor uses. Small calibre bullets for live quarry shooting – the outdoor shooting of live animals – and airguns are not in scope of the restriction.
Secretary for Health Prof Lo Chung-mau will depart for a visit to Nanjing tomorrow and return to Hong Kong the following day.
During the visit, Prof Lo will meet health officials of Jiangsu Province and introduce the latest developments of healthcare policies in Hong Kong to them.
He also plans to attend the 13th Nanjing Academic Symposium on Hepatobiliary Surgery & Liver Transplantation with the aim of deepening exchanges and collaboration on healthcare related areas with the Mainland.
As part of Prof Lo’s agenda, he will visit pharmaceutical companies and hospitals there to introduce the latest progress in enhancing Hong Kong’s drug approval mechanism and registration regime, and share the city’s experiences in strengthening hospital management and services.
During his absence, Under Secretary for Health Libby Lee will be Acting Secretary.
Don’t let the heatwave affect your medicines: Three important tips from the MHRA
Essential advice on protecting your medicines during extreme heat and staying safe this summer.
Woman cooling down with water and a fan
With the UK bracing for another heatwave this week, the Medicines and Healthcare products Regulatory Agency (MHRA) is reminding people that high temperatures can affect medicines and how well they work. Hot weather changes how your body responds to medications, which could impact people managing long-term conditions – but a few simple steps can help avoid problems.
Alison Cave, Chief Safety Officer at the MHRA, said:
“Let’s face it – when there’s a heatwave, most of us are focused on getting outside and enjoying it while it lasts. But it’s easy to forget that medicines left in the heat – in cars, bags, or on sunny windowsills – might not work properly when you need them.
“Some medicines can also make you more likely to burn in the sun, feel dizzy, or get dehydrated, especially if you’re taking diuetics or have a condition like asthma, heart disease, or diabetes.
“To stay safe in the heat:
Store medicines somewhere cool, dry and out of direct sunlight – especially if you’re out and about
Know the signs of heat-related illness – stay hydrated and listen to your body
Take extra care in the sun if your medicine makes your skin more likely to burn
“And remember, for all medicines it’s important to read the leaflet and speak to a healthcare professional if you have any questions.”
1. Keep medicines out of hot cars and direct sunlight
Most medicines need to be stored at temperatures below 25°C. But cars, trains and buses can heat up quickly during the summer, and rooms with direct sunlight can get much hotter than you’d think. Even bags and pockets can get warm enough to cause problems, especially if you’re out all day or at a festival, sports event, or the beach.
Heat can break down the active ingredients in medicines, meaning they might not work when you need them. That includes tablets, inhalers, hormone patches, insulin, and EpiPens. Some packaging will give clear storage instructions, but not all medicines come with a visible warning.
Medicines that need to be kept in the fridge – such as insulin or certain liquid antibiotics – are especially vulnerable to heat. If they’re left out too long or stored incorrectly, they may not work properly when you take them.
If your medicine has changed colour, developed an unusual smell, changed texture, or looks different in any way, this could signal heat damage. Ask your pharmacist for advice.
If you’re at home, check the patient information leaflet for storage instructions and keep medicines in the coolest part of the house, away from direct sunlight. If you’re travelling, avoid leaving them in parked vehicles or warm bags. A cool bag can help if you’re going to be out all day.
Heat damage can also affect how much medicine your body absorbs, potentially making your usual dose too strong or too weak. If you notice any changes in how you feel or how well your medicines seem to be working during hot weather, speak to your pharmacist or doctor.
Don’t forget medical devices:
It’s not just medicines – some medical devices can also be affected by heat or humidity. For example, blood glucose monitors may give people managing diabetes less reliable readings if used or stored in hot conditions.
Keep devices and any test strips somewhere cool and dry, and check the instructions that came with them for any temperature guidance. If your device isn’t behaving as expected, try running a control check or speak to your pharmacist for advice.
For more information about medicine safety, visit the MHRA website or report any concerns through the MHRA Yellow Card scheme.
2. Drink more water and stay cool if you’re taking water tablets or blood pressure medication
During hot weather, your body loses more water through sweating – but some medicines can make this worse, or make it harder for your body to cope with heat.
People taking diuretics, or ‘water tablets’, such as furosemide, are already losing more fluid through urination. This can cause dehydration and mineral imbalances. Blood pressure medicines such as ACE inhibitors, beta-blockers, or calcium channel blockers can also make it harder for your body to regulate temperature, especially during sudden hot spells. ACE inhibitors can even suppress your natural thirst response.
Some diabetes medicines, including insulin and metformin, also increase the risk of dehydration or make early symptoms harder to spot. Antipsychotic medications, such as olanzapine or quetiapine, or stimulant medications for attention disorders can increase your body temperature, making you overheat more easily.
Dehydration can cause dizziness, headaches, tiredness, confusion, and dark urine. This is particularly dangerous for older adults, young children, and people with heart or kidney conditions. If you start to feel unwell in the heat, move somewhere cooler, sip water slowly, and seek medical advice if you don’t feel better quickly.
3. Check if your medicine increases your risk of sunburn
Some common medicines can make your skin much more likely to burn, even in mild sunshine. This includes some antibiotics, diuretics, antidepressants, or skin treatments for acne or eczema. Painkillers such as ibuprofen or naproxen are also known to sometimes cause mild sun sensitivity, but this is less common and usually only a concern with frequent or long-term use.
One medicine that requires particular care is methotrexate, used to treat conditions like rheumatoid arthritis, psoriasis, Crohn’s disease and cancer. It can cause extreme skin sensitivity to the sun – even at low doses. This can lead to painful rashes, blistering, or swelling that looks like severe sunburn. In rare cases, these reactions have led to serious infections.
The risk goes up during sunny weather, especially if you’re outside more – whether you’re walking the dog, gardening, or heading off on holiday. Even a short walk at lunchtime or a train ride in the sun can be enough to trigger a reaction for some people.
If you take any medicines, always read the patient information leaflet or check with your pharmacist to see if sun sensitivity is a side effect.
The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating all medicines and medical devices in the UK by ensuring they work and are acceptably safe. All our work is underpinned by robust and fact-based judgements to ensure that the benefits justify any risks.
The MHRA is an executive agency of the Department of Health and Social Care.
For media enquiries, please contact the newscentre@mhra.gov.uk, or call on 020 3080 7651.
Government to align with European specifications on high risk in vitro diagnostic devices to reduce regulatory burden
The specifications will establish standards for high-risk diagnostic tests while creating consistency with European regulations
The Government has announced its intention to amend the Medical Devices Regulations 2002 for Great Britain to incorporate EU Common Specifications for high-risk in vitro diagnostic (IVD) devices and to repeal regulations on Coronavirus Test Device Approvals (CTDA).
Respondents overwhelmingly supported a proposal to repeal the current CTDA process for COVID-19 devices and to replace current requirements with Common Specifications. In the interim, an accelerated CTDA process will be introduced for COVID-19 devices that have CE marking under the European IVD regulations (EU IVDR) and meet Common Specification requirements.
The Common Specifications will also enhance performance standards for IVD devices related to infectious diseases including Hepatitis B, C and D, HIV and Syphilis, as well as devices for blood grouping and tissue typing. These diagnostic tools are critical for effective patient care and public health management.
The move aims to ensure these vital IVD devices, which test samples from the human body to monitor health or manage disease, meet high standards of performance backed by robust clinical evidence.
Rob Reid, Deputy Director of Innovative Devices at the MHRA, said:
By aligning with standards already in place across Europe, we’re not only enhancing patient safety but also making it easier for manufacturers to navigate regulatory requirements across different markets.”
These new specifications will be introduced in regulations expected to be published later this year as part of the Government’s broader programme of medical devices regulatory reform, which supports the NHS transformation.
The changes reinforce the Government’s commitment to reduce regulatory burden and balance robust patient safety measures with support for innovation in the medical technology sector.
ENDS
Notes to editors
Common Specifications refers to a set of standardised technical and performance requirements developed at the European level for certain high-risk in vitro diagnostic (IVD) medical devices.
In vitro diagnostic (IVD) devices are medical tests used to examine samples like blood, urine, or tissue taken from the human body to help detect, diagnose, or monitor diseases and health conditions.
The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating all medicines and medical devices in the UK by ensuring they work and are acceptably safe. All our work is underpinned by robust and fact-based judgements to ensure that the benefits justify any risks.
The MHRA is an executive agency of the Department of Health and Social Care.
For media enquiries, please contact the newscentre@mhra.gov.uk, or call on 020 3080 7651.
From 29 June to 4 July 2025, Zimbabwe conducted its second Joint External Evaluation (JEE) to assess the country’s capacity to prevent, detect, and respond to public health threats under the International Health Regulations (2005). The JEE, coordinated by the Ministry of Health and Child Care (MoHCC) with support from WHO and partners, marks a critical milestone in strengthening Zimbabwe’s public health emergency preparedness and response systems.
The JEE is a voluntary, collaborative process used globally to assess a country’s readiness to manage infectious disease outbreaks and other health emergencies. It is conducted every five years, with the country’s first evaluation completed in 2018.
“The JEE gives us a structured opportunity to check how ready we are to detect and respond to public health threats and we thank all the partners who have made this possible,” said Dr Wenceslaus Nyamayaro, MoHCC Acting Chief Director, Public Health.
The internal self-assessment, the first phase of the JEE, was completed in July 2025 with over 100 participants from across sectors including health, environment, veterinary services, defense, disaster management, civil society, and development partners including WHO, UNICEF, FAO, Africa CDC and others. This participatory process assessed 19 technical areas ranging from biosafety and surveillance to legislation and points of entry.
Key areas that emerged as requiring urgent attention include outdated or poorly implemented legal instruments, coupled with limited availability of legal support at subnational levels. Gender equity in emergencies remains a concern, with notable gaps in funding for gender-based violence (GBV) prevention and response, as well as low representation of women in emergency preparedness and decision-making processes. Funding for emergency response activities was also highlighted as inadequate. Surveillance systems for foodborne illnesses and healthcare-associated infections (HAIs) are still fragmented, highlighting the need for stronger cross-sector coordination. Coordination between the human, animal and environmental health sectors is still weak, showing the need to improve how these groups work together. Biosafety and biosecurity capacities also require strengthening, particularly in terms of laboratory infrastructure and staff training. Additionally, readiness at points of entry remains limited, with gaps in the ability to detect and respond to public health threats at borders and airports.
Zimbabwe also assessed its progress in tackling antimicrobial resistance (AMR), a growing global threat. While the country has developed a robust One Health AMR National Action Plan and established 14 multisectoral surveillance sites, challenges remain in laboratory capacity, integration of data systems and containment of multidrug-resistant organisms (MDROs).
The next phase of the JEE will involve an external validation mission scheduled for 6–13 September 2025. A team of international subject matter experts, coordinated by WHO’s Regional Office for Africa, will work with technical teams in Zimbabwe to validate scores, review documentation and conduct site visits to key health facilities including laboratories and points of entry. Following the mission, Zimbabwe will develop or update its National Action Plan for Health Security (NAPHS). This plan will consolidate findings from the JEE, past outbreak reviews, and risk assessments to guide future investments and reforms in public health preparedness.
“The evaluation is about continuous improvement. It reflects Zimbabwe’s commitment to protect the health of its people through stronger systems, better data, and broader collaboration,” said Dr. Desta Tiruneh, WHO Representative to Zimbabwe.
The evaluation was made possible with funding from the Health Resilience Fund (HRF) through WHO, with additional support mobilized by MoHCC from Africa CDC and UNICEF.
Distributed by APO Group on behalf of WHO Regional Office for Africa.
Undersecretary of State to the Presidency of the Council of Ministers Alfredo Mantovano chaired a meeting at Palazzo Chigi this evening between the Italian Government and a delegation from the Ukrainian Greek Catholic Church, led by the Major Archbishop of Kyiv-Halyč, His Beatitude Sviatoslav Shevchuk.
The meeting was also attended by: the Minister of Culture, Alessandro Giuli; the Minister of the Environment and Energy Security, Gilberto Pichetto Fratin; the Minister of Health, Orazio Schillaci; the Italian Ambassador to the Holy See, Francesco Di Nitto; the President of Triennale Milano, Stefano Boeri; the President of the MAXXI Foundation – National Museum of 21st Century Art, Emanuela Bruni; and, the President of the Bambino Gesù Foundation and Paediatric Hospital, Tiziano Onesti.
The meeting came just a few hours before the start of the 2025 Ukraine Recovery Conference (URC2025), which will be held in Rome tomorrow and the day after tomorrow, 10-11 July, and will be opened with addresses by the President of the Council of Ministers, Giorgia Meloni, and the President of Ukraine, Volodymyr Zelensky. In this regard, Undersecretary of State Mantovano thanked Archbishop Shevchuk “for having accepted the invitation for a discussion on the very eve of an international event dedicated to the reconstruction of war-torn Ukraine”.
The meeting reaffirmed the key role played by the Greek Catholic Church in providing the population with spiritual and social support over more than 40 months of conflict. “During these years – underlined Undersecretary of State Mantovano – you have demonstrated that you are a vibrant and united Church and community, able to respond as one, together with the other Christian Churches, to the suffering of your people”. There was a significant focus on the prospects for reconstruction and the role local communities and religious institutions can play in the country’s regeneration. “We are convinced – added Undersecretary of State Mantovano – that the ‘local dimension’ will be one of the pillars of Ukraine’s economic recovery. You too are among the representatives of local areas, demonstrating the crucial contribution believers can make in any context”.
Today’s meeting forms part of a broader cultural and social collaboration programme promoted by the Italian Government which, already since September 2023, has involved institutions such as Triennale Milano and MAXXI in initiatives dedicated to the restoration of war-damaged heritage, including the Transfiguration Cathedral in Odesa, and in training projects in the fields of cultural heritage conservation and management. At the end of the meeting, Undersecretary of State Mantovano presented His Beatitude Shevchuk with the bronze medal minted in 2024 by the Istituto Poligrafico e Zecca dello Stato [State Printing Works and Mint] to celebrate Ukraine’s resistance and support the ‘Unbroken Kids’ rehabilitation centre at the Saint Nicholas Children’s Hospital in Lviv.
WHO, in partnership with UNICEF, has published a new training manual to equip health and social care professionals and other workers to deliver effective and safe support to adults with mental health and psychosocial needs.
The manual provides a structured, competency-based approach to teaching and assessing foundational helping skills such as active listening, empathy and collaboration among specialist and non-specialist workers.
Globally, most people with mental health conditions do not receive effective care. For example, only 3% of individuals living with depression in low- and middle-income countries receive treatment, partly due to a shortage of well-trained mental health workers.
Everyone who is in a role supporting others – including health and social care professionals, community workers, counsellors, volunteers, and teachers ─ can benefit from evidence-informed training to improve foundational helping skills to assist with delivery of effective and safe support. Without these skills, there is a risk of ineffective, or even harmful, care.
“Millions of people cannot access quality mental health care because there simply aren’t enough trained specialists,” said Dévora Kestel, Director a.i., WHO Department of NCDs and Mental Health. “Strengthening foundational helping skills among non-specialists can help close this gap. This manual offers a practical, evidence-based path to equip helpers with the skills they need to provide effective, timely, and compassionate care to those who need it.”
Developed for the joint WHO-UNICEF EQUIP platform, the manual addresses gaps in training by offering a standardized, competency-based approach to teaching and assessing key foundational helping behaviours such as communication, empathy, collaboration, and promoting hope.
This manual equips trainers and supervisors with the tools to build helpers’ skills and confidence, ensuring care that is safe, respectful, and effective. It covers 15 core competencies and employs a validated approach to assess competency levels through structured role-plays. This competency-based approach helps reduce unhelpful or potentially harmful behaviours.
“The modular aspect of this manual makes it easy for trainers to integrate foundational helping skills in existing training courses. It can thus be flexibly adapted across health, social care, education, as well as humanitarian settings,” said Mark Van Ommeren, Mental Health Unit Head, WHO Department of NCDs and Mental Health.
Developed through expert consultation, literature review, and tested in four countries, the training has demonstrated improved competency and increased trainee confidence.
Trifork and Deloitte selected for Swiss Federal Office of Public Health’s DigiSanté framework agreement
Zurich – 10 July 2025
Trifork Switzerland has been selected as subcontractor to Deloitte Switzerland on the framework agreement for the lot “Expertise in the field of standards (author and developer) in the healthcare sector” under the DigiSanté program, led by the Swiss Federal Office of Public Health (FOPH/BAG).
This lot is part of the broader “DigiSanté – Health Business, Standards, Data Science, IT- and Data Security” framework, designed to strengthen the Swiss digital health infrastructure through standards-based development, secure data architecture, and modern health IT practices.
The agreement covers up to 144,000 hours over nine years across five awarded consortia, amounting to CHF 27.7 to 38.8 million. Specific tasks will be awarded through mini-tenders. While the total scope will depend on these future mini-tenders, this framework positions Deloitte and Trifork to contribute to high-impact healthcare digitalisation projects throughout the contract period.
“We are pleased to support the Swiss Federal Office of Public Health with our combined expertise in standards, interoperability, and healthcare system architecture. The DigiSanté framework is a cornerstone in the continued digital transformation of the Swiss healthcare system, and we look forward to collaborating closely with Trifork and health authorities.” — Rolf Brügger, Partner, Government & Public Services Industry Leader of Deloitte Switzerland
Trifork brings deep experience from regulated health software development, including CE-marked applications, shared care platforms, and interoperability services across European markets. In Switzerland, the company is actively involved in supporting nationwide initiatives such as the electronic patient dossier (EPD) and broader healthcare ecosystem projects. This builds on Trifork’s growing local presence through digital health partnerships and strategic investments.
“This collaboration is a natural extension of our commitment to digital health in Switzerland, and we’re excited to collaborate with Deloitte in this fascinating task. Our experience in standards implementation and healthcare-specific technology complements Deloitte’s strategic expertise, positioning us well to support FOPH’s long-term goals.” — Fabio Vena, CSO Trifork Switzerland
Press contact Frederik Svanholm, Group Investment Director, Head of IR & PR frsv@trifork.com, +41 79 357 7317
About the Federal Office of Public Health (FOPH / BAG) (bag.admin.ch) The Federal Office of Public Health (FOPH), part of the Swiss Federal Department of Home Affairs, is responsible for public health in Switzerland. The FOPH develops and implements national healthcare policy, ensures access to affordable, high-quality healthcare, and promotes the health and well-being of Switzerland’s population. As the lead authority behind the DigiSanté program, FOPH plays a key role in advancing Switzerland’s digital health infrastructure, setting standards for health data, and enabling secure, efficient and patient-centred health services across the country.
About Deloitte Switzerland (deloitte.ch) Deloitte offers integrated services that include Audit & Assurance, Tax & Legal, Strategy, Risk & Transaction Advisory, and Technology & Transformation. Its approach combines insight and innovation from multiple disciplines with business and industry knowledge to help clients excel anywhere in the world. With around 2,700 employees at six locations in Basel, Berne, Geneva, Lausanne, Lugano and Zurich (headquarters), Deloitte serves companies and organisations of all legal forms and sizes in all industry sectors. Deloitte AG is an affiliate of Deloitte North South Europe (NSE), a member firm of the global network of Deloitte Touche Tohmatsu Limited (DTTL) comprising around 460,000 employees in more than 150 countries.
About Trifork (trifork.com) Trifork (Nasdaq Copenhagen: TRIFOR) is a pioneering global technology company, empowering enterprise and public sector customers with innovative digital products and solutions. With 1,215 professionals across 71 business units in 16 countries, Trifork specializes in designing, building, and operating advanced software across sectors such as public administration, healthcare, manufacturing, logistics, energy, financial services, retail, and real estate. In Switzerland, Trifork is deeply involved in the healthcare tech ecosystem. The Group’s R&D arm, Trifork Labs, drives innovation by investing in and developing synergistic, high-potential technology companies.
Australia’s drug approval system is under fire, with critics in the United States claiming it is too slow to approve life-saving medicines.
Australia’s Therapeutic Goods Administration balances speed with a rigorous assessment of safety, efficacy and cost-effectiveness.
So does Australia really lag behind the US Food and Drug Administration? And do we need to change how we approve medicines?
The drug development pipeline
Drug development usually begins when something new is discovered about a disease. This usually involves identifying either a change in an important protein or finding a new protein involved in the disease.
When scientists know the shape of the protein, they can design a drug that can block or activate it.
Scientists will then undertake laboratory, petri dish-type, experiments to see if the drug works on the protein in the way they designed. If it passes those tests, they will then move onto animal testing and formulation.
Formulation is the step where scientists decide what form the medicine will take, such as a tablet, injection or patch. There are more than 150 different pharmaceutical dosage forms to choose from.
The final steps are human testing. This requires the completion of three types of clinical trials. Each seeks to answer different specific questions about the drug:
Phase I trials: is the drug safe? What are its side effects?
Phase II trials: does the drug work?
Phase III trials: is the drug better than currently available medicines?
At the end of the trials, a company can apply to the Therapeutic Goods Administration (TGA) for approval to market and sell the drug.
Getting a drug to market is time-consuming and costly. It takes around 15 years from the initial concept and design to government approval and costs more than A$3.5 billion.
But the failure rate is high: more than 90% of drugs that undergo development never gain government approval.
How are drugs approved in Australia?
The decision to approve new medicines for sale in Australia is made based on safety and efficacy evidence provided by the sponsoring company.
Listing a medicine on the Pharmaceutical Benefits Scheme (PBS) is a separate process from approval, and is based on financial considerations and a cost-benefit analysis, rather than safety and efficacy.
The TGA typically takes 240 to 260 working days (around a full calendar year) from receiving a new medicine application to an approval decision. This is longer than it takes the US Food and Drug Administration (FDA) – 180 to 300 days.
Where there is a pressing need, the approval process can be faster. The first COVID treatment was approved in Australia just two weeks after it was submitted for consideration.
Then why do Americans often get medicines first?
There can be several reasons why a drug approval can be delayed in Australia when it has already been approved overseas.
First, with a population of 27 million out of 8 billion world-wide, Australia is a relatively small market. So it is not always a high priority for companies to apply for approval here. Regions with large populations such as China, India and Europe are a bigger focus for companies. This can therefore delay when they submit to Australia.
Other reasons for delays can be that the TGA requires additional safety or efficacy evidence other regions did not request, or because new information about the drug has come to light since the drug was approved overseas.
What about delays getting drugs onto the PBS?
When a drug is listed on the PBS, Australians can access the medicine for $31.60 (or $7.70 concession) instead of the cost of a private prescription which might be hundreds or even thousands of dollars.
The time it takes for medicines to be approved on the PBS has also been a focus of criticism.
The Pharmaceutical Benefits Advisory Committee (PBAC), which makes PBS listing recommendations to the Federal Minister of Health, only sits three to six times per year.
US Chamber of Commerce vice president John Murphy claims the PBAC takes, on average, 32 months to make a recommendation about listing a drug after an application has been submitted.
Once a recommendation is made, the minister usually takes a minimum of five months to make a final decision.
To speed up the process, the TGA does allow parallel applications for drug approval and PBS listing.
The time taken to make a PBS listing decision is reasonable, given the scheme’s overall cost. In 2023–24, the total cost of the PBS to the government was $17.7 billion. So a decision to list can’t be made lightly.
So should Australia change how it approves medicines?
Criticising the time it takes to get regulatory approvals appears to be part of a wider plan of attack by the US government. It is putting pressure on Australia to open its market to higher prices for medicines made by US pharmaceutical companies.
Australia has a world-class regulatory agency in the TGA which ensures medicines that are approved are both safe and effective. And the PBS scheme is a key part of our public health care system and the envy of the world.
The Australian government should resist any changes to the regulatory approval processes that come from the US.
Nial Wheate in the past has received funding from the ACT Cancer Council, Tenovus Scotland, Medical Research Scotland, Scottish Crucible, and the Scottish Universities Life Sciences Alliance. He is a fellow of the Royal Australian Chemical Institute. Nial is the chief scientific officer of Vaihea Skincare LLC, a director of SetDose Pty Ltd (a medical device company) and was previously a Standards Australia panel member for sunscreen agents. He is a member of the Haleon Australia Pty Ltd Pain Advisory Board. Nial regularly consults to industry on issues to do with medicine risk assessments, manufacturing, design and testing.
Source: People’s Republic of China in Russian – People’s Republic of China in Russian –
An important disclaimer is at the bottom of this article.
Source: People’s Republic of China – State Council News
TEHRAN, July 10 (Xinhua) — Iranian Health Minister Mohammad Reza Zafarghandi said nearly 700 civilians were killed in Israeli attacks on Iran between June 13 and 24.
The minister made the remarks while addressing reporters on Tuesday while visiting a medical center in the capital Tehran, according to the Islamic Republic’s Health Ministry.
An Iranian minister said nearly 5,000 civilians had been injured in Israeli attacks, while 18 medical personnel, including six doctors, were among those killed in the airstrikes.
He noted that seven hospitals in the country were directly attacked by Israel, and some medical centers were evacuated.
The minister stressed that Israel also targeted 11 ambulances, adding that all these actions violate international principles and laws, as well as human rights. –0–
Please note: This information is raw content obtained directly from the source of the information. It is an accurate report of what the source claims and does not necessarily reflect the position of MIL-OSI or its clients.
▲ Galaxy Unpacked 2025 took place at Duggal Greenhouse in Brooklyn.
On July 9, Samsung Electronics hosted Galaxy Unpacked 2025 in Brooklyn — a borough known for its culture, creativity and spirit of collaboration. Under the theme of “Unfold Ultra,” the event reimagined what’s possible in the era of mobile AI. The all-new Galaxy Z Fold7, Galaxy Z Flip7, Galaxy Z Flip7 FE and Galaxy Watch8 series showcased seamless integration of Galaxy AI, redefined form factors and transformative performance.
Samsung Newsroom was on the ground at Galaxy Unpacked 2025, where the next chapter of mobile AI innovation unfolded.
Galaxy AI: A True AI Companion
▲ Roh opens the showcase by boldly announcing a new direction for Galaxy AI.
Building on a legacy of human-centered innovation, Samsung’s latest lineup reflects a clear vision — making AI more meaningful, personal and accessible. From slimmer foldables to personalized health-tracking wearables, these devices chart a bold trajectory for how AI companions can support users in every moment.
▲ Roh shares the vision for Galaxy AI as a true AI companion.
“When AI is paired with powerful mobile technology, it opens up a whole new world of opportunities,” said TM Roh, President, Acting Head of Device eXperience (DX) Division and Head of Mobile eXperience (MX) Business at Samsung Electronics. “The biggest breakthroughs are made when hardware, software and services challenge each other to grow.”
▲ The Galaxy Z Fold7 and Galaxy Z Flip7 are revealed through a launch video.
One UI 8: Made for Foldables, Powered by AI
▲ Won-Joon Choi, Chief Operating Officer of Mobile eXperience (MX) Business at Samsung Electronics, introduces One UI 8.
At the center of this transformation is One UI 8 — Samsung’s next-generation interface designed specifically for foldables, optimized for AI and built on the principles of multimodal understanding and deep personalization.
Privacy and security are core to One UI 8. The on-device Personal Data Engine learns from user preferences, while Knox Enhanced Encrypted Protection secures and isolates information within the app where it’s used.
Android 16 is available on the Galaxy Z Fold7 and Galaxy Z Flip7 at launch — made possible through close collaboration with Google.
▲ Rick Osterloh, Senior Vice President of Platforms & Devices at Google, discusses ongoing AI collaboration with Samsung.
Galaxy Z Fold7: A Larger Canvas for Galaxy AI
▲ Annika Bizon, Vice President of Product & Marketing at Samsung Electronics, highlights the Galaxy Z Fold7.
Pushing the limits of design, the Galaxy Z Fold7 is the slimmest Z Fold to date.
Features like Writing Assist and Drawing Assist help shape thoughts into polished prose and ideas into visuals. Now Brief displays insights — such as travel advisories, weather updates and exchange rates — by analyzing location, time and schedule.
▲ Circle to Search is demonstrated in a video.
Circle to Search has evolved to recognize in-game elements and provide contextual assistance without breaking immersion. Meanwhile, Vulkan optimizations boost graphics and responsiveness, powered by Snapdragon 8 Elite for Galaxy — engineered for next-level performance.
▲ The Galaxy Z Fold7 delivers next-generation resolution and effortless cropping.
For the first time, a 200-megapixel wide-angle camera headlines the Z Fold series, empowering users to shoot wide and crop tight without compromise. AI-powered editing tools have been optimized for the large display. Generative Edit now includes a new Suggest Erases feature that automatically detects and removes passersby. Audio Eraser offers intelligent sound isolation — with support for adjusting up to four sound types at once.
▲ Audio Eraser is demonstrated in a video.
Galaxy Z Flip7: A Full Experience, Even When Closed
▲ Dale Hogen, Mobile Communications at Samsung Electronics, reveals the Galaxy Z Flip7.
Compact yet uncompromising, the Galaxy Z Flip7 is the slimmest Z Flip yet. With a reengineered Flex Hinge and the largest battery in Galaxy Z Flip history, the device features a 6.9-inch bar-type display that delivers vivid visuals through an embedded polarizer.
The redesigned 4.1-inch FlexWindow spans edge to edge and supports a 120Hz refresh rate for ultra-smooth interaction. To maximize screen space, the bezel has slimmed to just 1.25 millimeters — nearly a third the thickness of its predecessor. Supporting numerous apps and widgets, One UI 8 brings greater functionality to the cover screen.
▲ The Galaxy Z Flip7 features a newly expanded Flex Window and thinner bezels.
The Galaxy Z Flip7 is a pocket-perfect AI assistant. Timely information — such as the day’s schedule or current playlist — appears on Now Bar. Meanwhile, holding the side button activates Google’s Gemini for hands-free AI. Gemini Live can even analyze outfits via the camera and suggest style tips based on the weather or calendar events.
▲ The Galaxy Z Flip7’s camera has FlexCam that allows users to take selfies in an easier way.
The 50-megapixel camera delivers sharp detail and true-to-life color thanks to the ProVisual Engine, and FlexCam gives users a one-of-a-kind selfie experience.
The revolutionary Galaxy Z Flip design is now even more accessible with the Galaxy Z Flip7 FE — featuring the same iconic foldable form, complete with a 50-megapixel camera, ProVisual Engine and Galaxy AI.
Galaxy Watch8: A New Standard for Personalized Health
▲ John Englehardt, Sales at Samsung Electronics, presents the Galaxy Watch8 series.
The Galaxy Watch8 series is an evolution in Samsung’s design philosophy to create a clearer, more iconic design identity with distinctive cushion design — first introduced on the Galaxy Watch Ultra. The slim design, combined with Dynamic Lug System provides an unparalleled all-day comfort. Galaxy Watch’s sleek form is complemented by its exceptional performance, with a new 3-nanometer processor, dual-frequency GPS and the advanced BioActive Sensor.
▲ Running Coach delivers personalized training.
The new Running Coach feature analyzes users’ running level and provides personalized insights to keep users motivated through the tailored coaching program. Simultaneously, Samsung Health informs users when it’s time to wind down via the new Bedtime Guidance feature.
▲ Vascular Load and other advanced health tracking features have been added.
Vascular Load monitors stress levels on the vascular system during sleep. Meanwhile, the Antioxidant Index uses the BioActive Sensor to measure carotenoid levels, delivering lifestyle insights for healthy aging.
The experience of having a true AI companion now comes full circle with the introduction of One UI 8 Watch across the Galaxy Watch8 series. In addition, the Galaxy Watch8 is the first smartwatch to come out of the box with Google’s Gemini and be powered by Wear OS 6.
Sustainability: A Commitment to the Planet
▲ This year’s Galaxy foldable align with Samsung’s sustainability vision.
Sustainability remains central to Galaxy’s design philosophy. The Galaxy Z Fold7 and Galaxy Z Flip7 incorporate nine recycled materials — including recycled lithium and plastics sourced from discarded fishing nets. These efforts align with Samsung’s broader Galaxy for the Planet initiative and reflect an enduring commitment to environmental stewardship.
The Experience Zone: A Galaxy of Possibilities, Unfolded
Attendees from around the world gathered in the product experience zone after the announcement, excited to explore the newly launched Galaxy devices. The Galaxy Z Fold7, in particular, drew attention for its noticeably slimmer, lighter build — with many eager to try it firsthand.
▲ The product experience zone draws a crowd at Galaxy Unpacked 2025.
“When I first saw the Galaxy Z Fold7, I was surprised by how slim and lightweight it is,” said Francisco Javier, a Samsung Member from Spain. “The larger screen makes a big difference.”
▲ Francisco Javier, a Samsung Member from Spain
“I love the Galaxy Z Flip7 because there are so many creative ways to use it,” said Ana Carolina Sandoval Diaz, an influencer from El Salvador. “I’m always making new content, and this gives me more freedom to do that.”
▲ Ana Carolina Sandoval Diaz, an influencer from El Salvador
“Samsung always surprises us — and this year, it’s how thin the Galaxy Z Fold7 is,” said Adi Fida, a journalist from Indonesia. “Despite the larger screen, it still feels easy to use with one hand.”
▲ Adi Fida, a journalist from Indonesia
“I like that the Galaxy Watch8 focuses on health,” said Bilge Suisik, an influencer from Türkiye. “I’ve never been great at sleeping, so I think it’ll help me get back on schedule — I could really use the reminders.”
▲ Bilge Suisik, an influencer from Türkiye
With the Galaxy Z Fold7, Galaxy Z Flip7, Galaxy Z Flip FE and Galaxy Watch8 series, Samsung has made a groundbreaking leap in delivering personalized, intelligent experiences that adapt, anticipate and empower. Galaxy AI is now more deeply embedded than ever across the Galaxy ecosystem — positioning Samsung at the forefront of a future where mobile technology is both personal and powerful.
Victorians will soon have greater access to free mental health and wellbeing support, with 7 new Mental Health and Wellbeing Locals set to open across the state.
These new services will build on the success of the 15 existing Mental Health and WellbeingLocals, which have already supported more than 21,000 people to access care closer to home – without the need for a referral or Medicare card.
The new services will be located in the Local Government Areas of:
Cardinia
Darebin
Maribyrnong
Maroondah
Mount Alexander (servicing Mount Alexander, Central Goldfields and Macedon Ranges)
Port Phillip
Wyndham.
The rollout of these new services is an important step in delivering on the Royal Commission’s vision for a connected, responsive and community-based mental health system.
ER Report: Here is a summary of significant articles published on EveningReport.nz on July 10, 2025.
How can we stay safe after data breaches? Step 1 is to change the cybersecurity laws Source: The Conversation (Au and NZ) – By Adam Andreotta, Lecturer, School of Management and Marketing, Curtin University Moor Studio / Getty Images Last week, Australian airline Qantas announced cyber attackers had accessed personal data about some of its customers. The company later confirmed that 5.7 million customer records were involved. The attackers targeted an
Cyber crime and real-world crime are converging in a dangerous new way – here’s how to stay safe Source: The Conversation (Au and NZ) – By Jongkil Jay Jeong, Senior Fellow, School of Computing and Information System, The University of Melbourne It starts with a call from someone claiming to be your bank. They know your name. They know your bank. They even know your credit card number. There’s been “unusual activity” on
Labor leads in two Victorian state polls, but Premier Jacinta Allan’s approval tanks Source: The Conversation (Au and NZ) – By Adrian Beaumont, Election Analyst (Psephologist) at The Conversation; and Honorary Associate, School of Mathematics and Statistics, The University of Melbourne Labor leads in Victorian state polls by Newspoll and Redbridge, but Premier Jacinta Allan is very unpopular. Two federal polls give Labor big leads and a Tasmanian
Cannabinoid products may reduce total sleep time in adults with insomnia: new study Source: The Conversation (Au and NZ) – By Camilla Hoyos, Senior Lecturer in the Centre for Sleep and Chronobiology, Macquarie University Lysenko Andrii/Shutterstock You might have heard cannabis and cannabinoid products can help people sleep. Data shows one of the top reasons people use cannabis is to help them sleep. But there’s a dearth of
Planning a ‘Euro summer’ or cruise? Why another flu shot might save your holiday Source: The Conversation (Au and NZ) – By Jack Janetzki, Lecturer in Pharmacy and Pharmacology, University of South Australia DavideAngelini/Shutterstock Are you escaping a southern hemisphere winter by heading off for a “Euro summer”? Maybe you’re planning a cruise through the Mediterranean. Or you’re dreaming of a white Christmas overseas later in the year. Maybe
Melting ice will strengthen the monsoon in northern Australia – but cause drier conditions north of the Equator Source: The Conversation (Au and NZ) – By Corey J. A. Bradshaw, Matthew Flinders Professor of Global Ecology and Node Leader in the ARC Centre of Excellence for Indigenous and Environmental Histories and Futures, Flinders University Sebnem Coskun/Anadolu via Getty Images Almost two-thirds of the world’s population is affected by the monsoon – the annual
Earth’s ‘oldest’ impact crater is much younger than previously thought – new study Source: The Conversation (Au and NZ) – By Aaron J. Cavosie, Senior Lecturer, School of Earth and Planetary Sciences, Curtin University Outcrops of shocked rocks from the Miralga impact structure. Aaron Cavosie Ever been late because you misread a clock? Sometimes, the “clocks” geologists use to date events can also be misread. Unravelling Earth’s 4.5-billion-year
Where do giant volcanic eruptions come from? New study finds missing link to ‘blobs’ deep within Earth Source: The Conversation (Au and NZ) – By Nicolas Flament, Associate Professor and ARC Future Fellow, Environmental Futures, School of Science, University of Wollongong Volcanic eruptions at Earth’s surface have significant consequences. Smaller ones can scare tourists on Mount Etna or disrupt air traffic. Giant, large-scale eruptions can have more serious impacts. One such event
Defence spending is like insurance – how will NZ pay the higher premiums? Source: The Conversation (Au and NZ) – By Stephen Hickson, Lecturer in Economics and Director, Business Taught Masters Programme, University of Canterbury Getty Images Defence spending is like insurance – you have to pay for it but you hope you never have to use it. And the higher the risk you face, the higher your
The Secret Lives of Mormon Wives shatters the church’s century-long effort to curate its own image Source: The Conversation (Au and NZ) – By Brenton Griffin, Casual Lecturer and Tutor in History, Indigenous Studies, and Politics, Flinders University Hulu Reality TV series The Secret Lives of Mormon Wives follows a number of social media influencers from the Church of Jesus Christ of Latter-day Saints who rose to prominence through social media,
We interviewed 205 Australians convicted of murder and manslaughter. Alcohol’s role was alarming Source: The Conversation (Au and NZ) – By Li Eriksson, Senior Lecturer, School of Criminology and Criminal Justice, Griffith University We’ve long known there’s a link between alcohol and violence, but when it comes to homicide the stories behind the statistics are harder to grasp. Our study sheds rare light on what actually happens when
Thirsty future: Australia’s green hydrogen targets could require vastly more water than the government hopes Source: The Conversation (Au and NZ) – By Madoc Sheehan, Adjunct Associate Professor in Chemical Engineering, James Cook University totajla/Shutterstock Green hydrogen is touted by some as the future – a way for Australia to slowly replace its reliance on fossil fuel exports. The energy-dense gas has the potential to reduce emissions in sectors challenging
Israel’s Rafah camp – ‘humanitarian city’ or crime against humanity? Source: The Conversation (Au and NZ) – By Shannon Bosch, Associate Professor (Law), Edith Cowan University Israel’s Defence Minister Israel Katz has announced a controversial plan to move up to 600,000 Palestinians in Gaza into a designated “humanitarian area” on the ruins of the southern city of Rafah. Access to the camp would be through
Ice baths are booming in popularity – but they come with health risks Source: The Conversation (Au and NZ) – By Samuel Cornell, PhD Candidate in Public Health & Community Medicine, School of Population Health, UNSW Sydney Michele Ursi/Getty Images Walk through any trendy suburb and you might find a new “wellness” studio offering ice baths or “contrast therapy” (a sauna and ice bath combo). Scroll social media,
Can’t fill your ADHD script? Here’s why, and what to do while the shortage persists Source: The Conversation (Au and NZ) – By Jack Janetzki, Lecturer in Pharmacy and Pharmacology, University of South Australia Attention-deficit hyperactivity disorder (ADHD) diagnoses are rising across Australia. But after finally getting a diagnosis, many people are discovering the medicine they’ve been prescribed isn’t available at the pharmacy. Australia faces a nation-wide shortage of methylphenidate
Medicinal cannabis is big business. But the latest clampdown won’t curb unsafe prescribing Source: The Conversation (Au and NZ) – By Carmen Lim, NHMRC Emerging Leadership Fellow, National Centre for Youth Substance Use Research, The University of Queensland Nuva Frames/Shutterstock Australia’s key regulator of health professionals has announced it’s clamping down on unsafe prescribing of medicinal cannabis in the wake of surging patient demand. The Australian Health Practitioner
Are ‘ghost stores’ haunting your social media feed? How to spot and avoid them Source: The Conversation (Au and NZ) – By Gary Mortimer, Professor of Marketing and Consumer Behaviour, Queensland University of Technology CC BY The offer pops up in your social media feed. The website is professional and the imagery illustrates an Australian coastal region, or chic inner-CBD scene. The brand name indicates this exclusive fashion retailer
NZ Post is the latest company to drop its climate targets – another sign business is struggling to decarbonise Source: The Conversation (Au and NZ) – By Pii-Tuulia Nikula, Associate Professor, School of Business, Eastern Institute of Technology Getty Images NZ Post committed to cutting its emissions by 32% by 2030 (based on 2018 levels), but recently announced it would abandon its climate target. The company was part of the Science Based Target initiative
Are you escaping a southern hemisphere winter by heading off for a “Euro summer”? Maybe you’re planning a cruise through the Mediterranean. Or you’re dreaming of a white Christmas overseas later in the year.
Maybe you’ve already booked your flights and accommodation, locked in your itinerary, and started planning what to pack.
But there may be one more thing to add to your pre-travel checklist – a flu shot.
For some travellers, this may mean a second flu shot this year – one for Australia’s flu season and another to protect them in the northern hemisphere.
Why do I need another flu shot?
Protection from a flu shot doesn’t last all year; it decreases after three to four months.
So if you had your flu shot in April or May, it may no longer offer enough protection by the time you travel in July or later.
Getting a second shot will provide you with optimal protection against the flu while travelling to the northern hemisphere.
That’s why it is now recommended Australians travelling to the northern hemisphere between October and May consider a second flu shot if they’ve already had one earlier this year.
If it’s been three to four months since your first shot, you can consider a second shot.
A second shot should be at least four weeks after the first shot. Ideally, get your second shot at least two weeks before your departure, so your body has time to build up protection.
If you haven’t had a flu shot at all this year, now’s the time. In the year to July 7, there have been more than 167,000 confirmed cases of the flu in Australia.
Who should consider a second flu shot?
Here are some examples where a second flu shot is worth discussing with your doctor or pharmacist.
Cruises are a prime setting for flu outbreaks. There are hundreds or thousands of people sharing confined spaces, such as restaurants and entertainment facilities, for days or weeks at a time. This creates the perfect environment for the flu virus to spread.
Group tours and large events are also high risk. Bus tours, music festivals and cultural events bring together large crowds, often in indoor spaces or via shared transport. This increases your chance of exposure and catching the virus.
Pilgrimages and religious gatherings such as Hajj, Lunar New Year or Ramadan are also high risk, especially for older travellers or those with health conditions. These events can attract millions of international visitors, often in crowded, shared accommodation, where flu and other respiratory viruses can spread rapidly.
People who are over 65 years of age, have medical conditions, such as severe asthma or diabetes, or are on medications that decrease their immune function, are more likely to become severely ill if they catch the flu. So, if you’re travelling during the northern hemisphere’s flu season, a second shot should be strongly considered.
Which flu shot should I get?
Each year, health authorities around the world develop two different flu shots, one for each hemisphere’s flu season. The flu shots can differ, as flu strains change rapidly and different strains may circulate in different regions.
Australians receive the southern hemisphere version around March to May. And
while it’s ideal to have the northern hemisphere flu shot before heading overseas, it’s not available in Australia.
Instead, you can have two shots of the southern hemisphere flu shot – one earlier in the year and a second shot before your trip.
You could wait until you are overseas to get your second shot. But you wouldn’t be protected for two weeks afterwards, and you’d need to navigate an overseas health system while on holiday.
Where can I get a flu shot? How much does it cost?
You can get a flu shot at your local pharmacy, GP clinic, or sometimes via your workplace. Many pharmacies offer walk-in appointments, and the flu shot usually costs around A$25 (including the price of the vaccine and administering it).
If your GP doesn’t bulk bill, you will be charged an out-of-pocket cost for the consultation, and may need to pay the cost of the shot if you don’t qualify for a free one.
The (first) flu shot is free for people who meet certain criteria, such as being 65 and over, pregnant, Aboriginal and Torres Strait Islander people and those with certain medical conditions. But you would have to pay for a second shot if you’re travelling.
Specific flu shots are recommended for each person. So speak to your pharmacist or GP to discuss the best option for you.
Your GP or pharmacist will also discuss what to expect after your flu shot. This may include tiredness, fever, muscle aches, and redness or swelling at the injection site. These usually go away within two days. For most people, these symptoms are mild and well-tolerated.
Why bother?
The flu is more than just a sniffle. It can lead to serious illness, cancelled plans and perhaps a hospital stay in a foreign country. Even if you don’t get sick, you could pass the virus to others more vulnerable than yourself.
So before you finish your pre-travel checklist, make sure your flu shots are up to date.
Not getting the shot could be the difference between sipping Aperol spritz on the Amalfi Coast or spending your trip in bed with a fever.
Jack Janetzki works for the University of South Australia, Pharmaceutical Defence Limited and The Barossa Pharmacist in the Mall (Nuriootpa, South Australia). He is a member of Pharmaceutical Defence Limited, the Australasian Pharmaceutical Science Association, the Pharmaceutical Society of Australia, the South Australian Immunisation Program Advisory Group, the Observational Health Data Science Informatics network and the International Pharmaceutical Federation (FIP) Insight Board for pharmacist-led vaccination services.
Wern Chai is employed as a lecturer at the University of South Australia. He is an SME for the Australian Pharmacy Council, a board examiner for the Pharmacy Board of Australia, the Australasian Pharmaceutical Science Association, Pharmaceutical Society of Australia, the South Australian Immunisation Program Advisory Group and the International Pharmaceutical Federation (FIP) Insight Board for pharmacist-led vaccination services.
You might have heard cannabis and cannabinoid products can help people sleep. Data shows one of the top reasons people use cannabis is to help them sleep.
But there’s a dearth of high-quality research on how medicinal cannabis products actually affect sleep.
To find out more, our research team conducted a small pilot study involving 20 people. We wanted to compare how they slept after using a medicinal cannabis product, compared to a placebo.
We found a single oral dose of a cannabinoid product decreased total sleep time and the time spent in REM sleep (rapid eye movement, which is when we tend to dream). We didn’t observe any change in objective alertness the day after the treatment.
Our study is small and only measured the effect of a single dose, so more research is clearly needed.
But overall, our findings suggest cannabinoids may acutely influence sleep, primarily by suppressing REM sleep, without noticeable next-day impairment.
What we did
All 20 people (16 of whom were female) involved in our study had a clinical diagnosis of insomnia disorder.
This means they reported having challenges falling asleep and/or maintaining sleep and that these disturbances impact day-to-day functioning socially, at work, or in other important areas of life.
The average age of our study participants was about 46 years.
At our lab, the study participants were interviewed by a doctor and had their medical history taken. All participants also underwent an overnight diagnostic sleep study. This was done to confirm their sleeplessness was truly insomnia and not other conditions such as sleep apnoea.
Once the participant was able to start the study, they were asked to sleep for two nights at our lab, with at least one week between those two visits.
On one of their visits, they were given a placebo.
On the other, they were given a single oral dose of a medical-grade cannabis oil containing 10 mg THC (tetrahydrocannabinol, the compound responsible for the psychoactive effects of cannabis) and 200 mg CBD (cannabidiol, which does not produce a “high”).
Using a product with a precise, known dose ensures the results are relevant to what doctors in Australia are already prescribing.
The order in which participants received either the treatment or the placebo was randomised, so they didn’t know which one they were taking.
After taking either the treatment or the placebo, they slept at our lab while wearing a special cap with 256 monitors on it. This high-density electroencephalogram or EEG allowed us to record the electrical activity of the brain while the person slept.
The next morning, after they either woke or were woken, they performed a driving simulation test around the time of their normal morning commute.
They also underwent a test that assessed their ability to stay awake in a quiet, dimly lit environment. To track their alertness throughout the day, they repeated this test four times while wearing the high-density EEG cap. This was so we could test their alertness the day after either the treatment or the placebo.
What we found
Our results were not what we expected.
We found the THC/CBD treatment decreased total sleep time by an average of 24.5 minutes. This was largely driven by a significant impact on REM sleep (the phase associated with dreaming), which not only decreased by an average of 33.9 minutes but also took significantly longer for participants to enter. The treatment also offered no benefit in helping participants stay asleep throughout the night.
Perhaps most intriguingly, this objective worsening of sleep wasn’t reflected in the participants’ own perceptions; they reported no change in their subjective sleep quality. This disconnect continued into the next day.
While participants noted feeling slightly more sleepy after the treatment, their objective alertness – measured by their ability to stay awake in a quiet, dimly lit room – was reassuringly unchanged, as was their cognitive and simulated driving performance.
This leads to a crucial question: if a single dose produces these changes, what are the cumulative effects on a person’s sleep after weeks, months, or years of nightly use?
We simply don’t have the answers yet, especially with a medical-grade cannabis product.
A growing body of research
Our findings underscore a significant gap between the widespread public perception of cannabis for sleep and the complex scientific reality. As highlighted by a review we published in the journal Current Psychiatry Reports, the evidence base remains thin.
We reviewed 21 recent studies (published between 2021 and 2024) of cannabinoids being used for insomnia, subjective sleep impairment, obstructive sleep apnoea, rapid eye movement sleep behaviour disorder, and restless legs syndrome.
We found that, despite its widespread use, there’s not enough research yet to support the use of medical cannabis to treat sleep disorders.
This is why this kind of research is so vital. It provides the first pieces of a much larger puzzle.
To give doctors and patients the clear guidance they need, there is an urgent need for adequately funded, well-designed clinical trials with larger sample sizes and longer treatment durations to truly understand the long-term impacts of medicinal cannabis on sleep and daytime functioning.
Camilla Hoyos is a Research Leader within the Centre for Sleep and Chronobiology at the Woolcock Institute of Medical Research. The Woolcock sleep group received funding from Lambert Initiative of Cannabinoid Therapeutics (a philanthropic centre based at The University of Sydney) for this study and for another unpublished trial in the same space. Woolcock sleep group also received funding to be a site on an industry-sponsored clinical trial on a cannabinoids medicine in insomnia. Camilla Hoyos is also a board member of the Australasian Sleep Association. This study described in this article was a collaboration between the Woolcock Institute of Medical Research and Lambert Initiative of Cannabinoid Research.
Anastasia has previously received funding from the Lambert Initiative for Cannabinoid Therapeutics, a philanthropically funded research initiative at the Brain and Mind Centre, University of Sydney. She has received consulting fees from the Medicinal Cannabis Industry Australia for a commissioned review article and Haleon (a consumer health-care subsidiary of GSK) for non-cannabinoid related work. She is a committee member for the Sleep Health Week Working Party and an expert speaker for the Sleep Health Foundation.
You might have heard cannabis and cannabinoid products can help people sleep. Data shows one of the top reasons people use cannabis is to help them sleep.
But there’s a dearth of high-quality research on how medicinal cannabis products actually affect sleep.
To find out more, our research team conducted a small pilot study involving 20 people. We wanted to compare how they slept after using a medicinal cannabis product, compared to a placebo.
We found a single oral dose of a cannabinoid product decreased total sleep time and the time spent in REM sleep (rapid eye movement, which is when we tend to dream). We didn’t observe any change in objective alertness the day after the treatment.
Our study is small and only measured the effect of a single dose, so more research is clearly needed.
But overall, our findings suggest cannabinoids may acutely influence sleep, primarily by suppressing REM sleep, without noticeable next-day impairment.
What we did
All 20 people (16 of whom were female) involved in our study had a clinical diagnosis of insomnia disorder.
This means they reported having challenges falling asleep and/or maintaining sleep and that these disturbances impact day-to-day functioning socially, at work, or in other important areas of life.
The average age of our study participants was about 46 years.
At our lab, the study participants were interviewed by a doctor and had their medical history taken. All participants also underwent an overnight diagnostic sleep study. This was done to confirm their sleeplessness was truly insomnia and not other conditions such as sleep apnoea.
Once the participant was able to start the study, they were asked to sleep for two nights at our lab, with at least one week between those two visits.
On one of their visits, they were given a placebo.
On the other, they were given a single oral dose of a medical-grade cannabis oil containing 10 mg THC (tetrahydrocannabinol, the compound responsible for the psychoactive effects of cannabis) and 200 mg CBD (cannabidiol, which does not produce a “high”).
Using a product with a precise, known dose ensures the results are relevant to what doctors in Australia are already prescribing.
The order in which participants received either the treatment or the placebo was randomised, so they didn’t know which one they were taking.
After taking either the treatment or the placebo, they slept at our lab while wearing a special cap with 256 monitors on it. This high-density electroencephalogram or EEG allowed us to record the electrical activity of the brain while the person slept.
The next morning, after they either woke or were woken, they performed a driving simulation test around the time of their normal morning commute.
They also underwent a test that assessed their ability to stay awake in a quiet, dimly lit environment. To track their alertness throughout the day, they repeated this test four times while wearing the high-density EEG cap. This was so we could test their alertness the day after either the treatment or the placebo.
What we found
Our results were not what we expected.
We found the THC/CBD treatment decreased total sleep time by an average of 24.5 minutes. This was largely driven by a significant impact on REM sleep (the phase associated with dreaming), which not only decreased by an average of 33.9 minutes but also took significantly longer for participants to enter. The treatment also offered no benefit in helping participants stay asleep throughout the night.
Perhaps most intriguingly, this objective worsening of sleep wasn’t reflected in the participants’ own perceptions; they reported no change in their subjective sleep quality. This disconnect continued into the next day.
While participants noted feeling slightly more sleepy after the treatment, their objective alertness – measured by their ability to stay awake in a quiet, dimly lit room – was reassuringly unchanged, as was their cognitive and simulated driving performance.
This leads to a crucial question: if a single dose produces these changes, what are the cumulative effects on a person’s sleep after weeks, months, or years of nightly use?
We simply don’t have the answers yet, especially with a medical-grade cannabis product.
A growing body of research
Our findings underscore a significant gap between the widespread public perception of cannabis for sleep and the complex scientific reality. As highlighted by a review we published in the journal Current Psychiatry Reports, the evidence base remains thin.
We reviewed 21 recent studies (published between 2021 and 2024) of cannabinoids being used for insomnia, subjective sleep impairment, obstructive sleep apnoea, rapid eye movement sleep behaviour disorder, and restless legs syndrome.
We found that, despite its widespread use, there’s not enough research yet to support the use of medical cannabis to treat sleep disorders.
This is why this kind of research is so vital. It provides the first pieces of a much larger puzzle.
To give doctors and patients the clear guidance they need, there is an urgent need for adequately funded, well-designed clinical trials with larger sample sizes and longer treatment durations to truly understand the long-term impacts of medicinal cannabis on sleep and daytime functioning.
Camilla Hoyos is a Research Leader within the Centre for Sleep and Chronobiology at the Woolcock Institute of Medical Research. The Woolcock sleep group received funding from Lambert Initiative of Cannabinoid Therapeutics (a philanthropic centre based at The University of Sydney) for this study and for another unpublished trial in the same space. Woolcock sleep group also received funding to be a site on an industry-sponsored clinical trial on a cannabinoids medicine in insomnia. Camilla Hoyos is also a board member of the Australasian Sleep Association. This study described in this article was a collaboration between the Woolcock Institute of Medical Research and Lambert Initiative of Cannabinoid Research.
Anastasia has previously received funding from the Lambert Initiative for Cannabinoid Therapeutics, a philanthropically funded research initiative at the Brain and Mind Centre, University of Sydney. She has received consulting fees from the Medicinal Cannabis Industry Australia for a commissioned review article and Haleon (a consumer health-care subsidiary of GSK) for non-cannabinoid related work. She is a committee member for the Sleep Health Week Working Party and an expert speaker for the Sleep Health Foundation.
Source: United States Senator for Tennessee Bill Hagerty
WASHINGTON—Today, United States Senator Bill Hagerty (R-TN) announced 6 additions to his staff in Tennessee and Washington, D.C. Hagerty’s team continues to be fully operational and serving the great state of Tennessee.
Brian McCormack will soon assume the role of Chief of Staff. McCormack is currently serving as the Chief of Staff for the National Security Council at the White House. Previously, he served at the White House Office of Management and Budget responsible for nearly a dozen agencies and as the Chief of Staff at the Department of Energy. The current Chief of Staff, Adam Telle, was nominated in March by President Trump to serve as the Assistant Secretary of the Army for Civil Works where he will oversee the Corps of Engineers.
“I’m glad to have someone of Brian’s caliber and experience to lead this exceptional team. He brings a set of highly-relevant perspectives to the role where the paramount focus is to serve the people of Tennessee and the interests of our nation,” said Senator Bill Hagerty. “Brian’s background and relationships within the Trump Administration will support my objective of making the federal government work for the American people.”
“I’m thankful for the many years of service Adam has put in leading our team from day one in the Senate, which has helped me build a strong foundation for success here in the U.S. Senate going forward,” said Senator Bill Hagerty. “I’m so proud of the opportunity he’s been given to once again serve as an outstanding member of President Trump’s administration, and his management of the Corps of Engineers will bring the responses we’ve seen in my Senate office to bear on an organization central to Tennessee and our nation.”
Robert Donachie is now serving as Deputy Chief of Staff for Communications. Donachie served as Vice President of a Washington, DC-based public relations and literary agency. He spent several years working in the House of Representatives. He also served as the White House correspondent for The Washington Examiner and as a political reporter for The Daily Caller. Donachie has appeared on Fox News Channel, nationally syndicated radio programs, and provided commentary for The New York Times, POLITICO, Newsweek, The Hill, and other outlets.
Tiffany Delgado recently joined as Deputy Chief of Staff for Operations, replacing Jim Durrett. Delgado served as Senior Vice President of a Washington, DC-based marketing agency specializing in custom targeted voter contact, fundraising and issue advocacy programs, where she was recognized with the Rising Star Award from Campaigns and Elections. Previously she worked at the National Republican Senatorial Committee as the Director of Direct Response. Tiffany holds a B.A. from the University of Virginia, and is currently pursuing her MBA from Georgetown University.
Michael Sullivan will become Senior Advisor to Senator Hagerty, where he will continue to be involved in state operations while also providing strategic advice on the Senator’s larger operation, leveraging Sullivan’s experience to benefit Hagerty’s broader mandate.
Alec Richardson will become the State Director for Senator Hagerty. Currently, he serves as Senior Advisor to Governor Bill Lee and Director of External Affairs at the State of Tennessee. In this role, Richardson is responsible for overseeing strategic operations, managing federal relations, and advising on key legislative issues. He formerly served as Deputy Chief of Staff and Personal Aide to the Governor. He resides in Nashville with his wife and their one-year-old son.
Kalleigh Ahern is now serving as Press & Digital Assistant in the office of U.S. Senator Bill Hagerty. Prior to joining the Senate, she worked as a Public Relations and Communications Intern at a national PR agency, where she contributed to strategic campaign planning, media monitoring and cross-sector client research. Ahern also gained firsthand experience in federal outreach and constituent services while working in her home congressional district in Tennessee. She graduated summa cum laude from The University of Alabama with a focus in public relations and political science.
Serving in the Trump Administration
Adam Telle has been advanced out of the Armed Services Committee and Environment and Public Works Committee to lead the U.S. Army Corps of Engineers as Assistant Secretary of the Army for Civil Works. Telle has served as Hagerty’s Chief of Staff over the last four years and will continue to serve Hagerty while his nomination is pending before the Senate. Telle served during the first Trump Administration as the White House’s Senate lead in its Office of Legislative Affairs. Prior to that role, Telle served as the top staff member on the Senate Appropriations Committee’s Subcommittee on Homeland Security and as the top policy advisor to the late Senator Thad Cochran. Telle holds degrees in computer science and journalism from Mississippi State University.
Jim Durrett is now the Deputy Chief of Staff to the Vice President and Deputy Assistant to the President. Previously, he served as Deputy Chief of Operations for Senator Hagerty. Durrett is a native of Clarksville, Tennessee.
Luke Pettit has been advanced out of the Banking, Housing, and Urban Affairs Committee to be Assistant Secretary of the Treasury for Financial Institutions. Pettit has served as Senator Hagerty’s Senior Policy Advisor and will continue to serve Hagerty while his nomination is pending before the Senate. Previously, he worked at the Senate Banking Committee, Bridgewater Associates, and the Federal Reserve. Luke holds a B.A from the University of Pennsylvania, and graduate degrees from the London School of Economics and Johns Hopkins University.
Jonathan Greenstein is nominated to be Deputy Undersecretary of the Treasury for International Finance. Previously, he served as Senator Hagerty’s Senior Policy Advisor. Greenstein is a graduate of Harvard Business School and Yale Law School.
Daniel Zimmerman has been confirmed to be the Assistant Secretary of Defense for International Security Affairs. Zimmerman previously served in a Congressional Executive Fellowship in the office of Senator Hagerty. He previously has held many roles in the agency realm, and holds both a bachelor’s degree from Asbury University and a master’s degree from the Patterson School of Diplomacy at the University of Kentucky.
Julia Hahn is serving as the Assistant Secretary of the Treasury Department for the Office of Public Affairs. Hahn joins the Department after serving as Deputy Chief of Staff for Communications for Senator Hagerty. Prior to the Senate, Hahn served in the first Trump White House over all four years, most recently as Deputy Assistant to the President and Deputy White House Communications Director. Before that, she served as Special Assistant to the President and Director of Rapid Response and Surrogate Operations. Hahn has also worked in media as the Executive Producer of The Laura Ingraham Show and a reporter at Breitbart News. She also worked on Capitol Hill as Press Secretary to former Congressman Dave Brat. Hahn graduated from the University of Chicago with a BA in Philosophy.
Clark Milner is serving as Special Assistant to the President and Senior Advisor for Policy, focusing primarily on domestic policy. Milner formerly served as Deputy Chief of Staff for Policy and Chief Counsel to Senator Bill Hagerty. Milner previously served as Deputy Counsel to Governor Bill Lee.
Natalie McIntyre currently serves as a Special Assistant to the President for the Office of Legislative Affairs where she handles the Healthcare, Education, Labor, Banking, and Agriculture portfolio. Previously, she was Senator Hagerty’s Legislative Director overseeing the legislative team and managing the Health, Education, Labor, Pension, and Veterans portfolio. Prior to her role in Hagerty’s office, she was part of the legislative office at OMB where she managed the Senate offices. She also served as a Senior Policy Advisor and White House liaison at ONDCP.
Jason Hoffman is currently the Executive Secretary at the White House Office of Management and Budget. Hoffman formerly served as a Policy Advisor for Senator Hagerty, focusing on homeland security and judiciary issues. Previously, he worked at the Office of Management and Budget during President Trump’s first term and as a Legislative Assistant in the U.S. House of Representatives.Nels Nordquist is serving as Deputy Assistant to the President for International Economic Policy and Deputy Director of the National Economic Council. Nordquist was Senior Fellow for Economic Policy in the office of Senator Hagerty. In addition, his prior service includes as Staff Director for the National Security, Illicit Finance, and International Financial Institutions Subcommittee of the House Financial Services Committee. From 2018-2021, Nordquist worked in the National Security Council and National Economic Council, first as Director for Trade & Investment and later as Special Assistant to the President and Senior Director for International Economic Policy. Nordquist graduated from Stanford and earned an MBA from the University of Virginia.
Joel Rayburn is the Trump Administration’s nominee to be Assistant Secretary of State for Near Eastern Affairs. He is a historian, former diplomat, and retired military officer who previously served as special advisor for Middle East affairs in the office of Senator Hagerty. Rayburn is currently a senior fellow at the Hudson Institute. In the first Trump Administration, he served as a senior director on the National Security Council staff and, from July 2018 to January 2021, as the U.S. special envoy for Syria. Before joining the State Department, Rayburn served 26 years as a US Army officer and co-authored the Army’s official history of the Iraq War. He holds an MA in history from Texas A&M University and an MS in strategic studies from the National War College.
Kevin Kim serves as Deputy Assistant Secretary of State in the State Department’s Bureau of East Asian and Pacific Affairs. He previously worked as a National Security Fellow for Senator Hagerty. Kim was also the Senior Advisor to the Special Presidential Envoy for Arms Control Marshall Billingslea as part of the U.S. delegation to the 2020 U.S.-Russia arms control negotiations. From 2018 to 2020, he served as the Chief of Staff to the Special Representative for North Korea and the Deputy Secretary of State Stephen Biegun and worked closely with then-U.S. Ambassador to Japan Hagerty as he participated in various rounds of U.S.-DPRK nuclear negotiations. Kim received a BA from the Johns Hopkins University, MA from the Johns Hopkins University School of Advanced International Studies, and is currently pursuing a Doctorate in International Relations from the Johns Hopkins University School of Advanced International Studies.
Daniel Tirosh now serves on the National Security Council. Tirosh previously served as Deputy National Security Advisor and Counsel for Senator Hagerty. He holds a bachelor’s degree from University of California, Santa Cruz, and graduated from Stanford Law School.
Walton Stivender Mears has taken on a new role as scheduler for Housing and Urban Development Secretary Scott Turner. Mears joined HUD earlier this year after serving as Director of Scheduling for Senator Hagerty. She previously handled scheduling and assisted the chief of staff for Sen. Roger Marshall (R-KS) and as a Staff Assistant for Senator Richard Shelby (R-AL). Mears is a graduate of Auburn University.
J. Cal Mitchell is serving as Special Advisor for the Office of Legislative Affairs at the U.S. Department of Treasury. He joins the Treasury Department after serving as Personal Aide to Senator Hagerty. Mitchell is a graduate of Hampden-Sydney College.
Nick Checker, a former national security fellow for Senator Hagerty, currently serves as Deputy Executive Secretary on the National Security Council. In that role, Checker provides senior-level review of NSC products for substance, policy relevance, and appropriateness for the President and senior White House officials. Checker has spent the last decade prior to his service on Senator Hagerty’s staff at the Central Intelligence Agency (CIA) as a military analyst covering conflicts in the greater Middle East. Most recently, Checker worked in CIA’s office of Congressional Affairs, where he supported the confirmation process for Director John Ratcliffe. He holds a bachelor’s degree in history and political science from the University of Wisconsin and a master’s degree in Security Studies from Georgetown University.
Nicholas Elliot is the Confidential Assistant and Policy Advisor to the President’s Council of Advisors on Digital Assets. Previously, Elliot worked on Senator Hagerty’s 2020 campaign team and spent nearly four years working for Senator Hagerty on the Senator’s financial services and banking portfolio, where he advanced the Senator’s work on the Committee on Banking, Housing, and Urban Affairs. Elliot is a graduate of Georgetown University’s McDonough School of Business where he received a BS in Business Administration with a major in Finance and a minor in Mandarin.
Taylor Asher serves as Senior Policy Advisor to Chairman Paul Atkins. From April 2023 to January 2025, Asher served as Policy Advisor and Confidential Assistant to Commissioner Uyeda. Prior to his time at the SEC, Asher was Personal Aide to Senator Hagerty. His tenure in public service began with Congresswoman Julia Letlow’s Office, where he served as Staff Assistant and Intern Manager. Asher is currently pursuing a Master of Economics at George Mason University. He holds a Master of Finance with an Energy Specialization as well as a Bachelor of Science in Management from Tulane University. He is originally from Nashville, Tennessee.
Cole Bornefeld will be serving as Director of Correspondence for the Office of the Vice President. He previously served as a Legislative Aide to Hagerty, assisting in the Judiciary, Homeland Security, Commerce, and Rules portfolio. Bornefeld previously served as a Legislative Correspondent, Staff Assistant, and Intern in Senator Hagerty’s office. He graduated from Western Kentucky University with a bachelor’s degree in political science and public relations.